SERVICES

Close-up TV News - Prolotheray lecture

Reversing Hypertension

Heavy Metals and all diseases

Close-Up TV News - Dr. Calapai's approach

News 12 Interview: Parkinson’s Disease, Glutathione and Chelation Therapy

News 12 Interview: Platelet-rich plasma therapy

Prolotherapy Interview News 12

News 12 Interview: Diabetes and Weight Loss
Effect of POLY-MVA, a palladium α-lipoic acid complex formulation against declined mitochondrial antioxidant status in the myocardium of aged rats

Palladium α-lipoic acid formulation – ‘POLY-MVA’ is found to enhance the activities of Krebs cycle dehydrogenases and respiratory complexes in the heart of aged rat. In this study, we aimed to evaluate the effect of POLY-MVA on the activities of antioxidant status in the heart mitochondria of aged rat. We determined the activities of manganese–superoxide dismutase (Mn SOD), catalase (CAT), glutathione peroxidase (GPx), and level of reduced GSH and lipid peroxidation in the heart mitochondria of aged rats, after administering POLY-MVA (0.05 ml/kg; equivalent to 0.38 mg complexed α-lipoic acid/kg) orally once daily for 30 days. DL-α-lipoic acid (0.38 mg/kg, p.o) treated for 30 days was kept as the positive control. We found that the antioxidant in the aged control was declined significantly than the young control. The formulation significantly (p < 0.05) enhanced the activity of CAT and GPx compared to the aged control. The level of GSH was also significantly improved and the level of lipid peroxidation was decreased significantly (p < 0.05) by POLY-MVA. The results indicate that POLY-MVA is effective to protect the age-linked decline of myocardial mitochondrial antioxidant status. The findings suggest the use of this formulation against myocardial aging.

Published on 08-01-2013